Crohn's Disease
Co inheritance of variants/mutations in Malaysian patients with Crohn s disease
... Crohn’s disease (CD) is a major form of chronic inflammatory bowel disease, apart from ulcerative colitis (Sugimura et al., 2003). CD usually causes swelling in the intestines, and can affect any part of ...
7
Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on Nutrition and autoimmune disease Nutrition in Crohn s disease
... Crohn’s disease remains unknown. The consensus is that the disease results from a complex interaction between genes, immunity and environmental ...the disease but are likely to be overt during acute ...
8
Running Head: Diagnosis and Treatment of Crohn s Disease 1
... Crohn’s disease that may require surgery include: intestinal obstructions or blockage, excessive bleeding in the intestine, perforation of the bowel, formation of a fistula or abscess, and toxic ...Crohn’s ...
13
Short Bowel Syndrome and Crohn s Disease
... Crohn’s disease can affect any part of the gastrointestinal tract, from the mouth to the ...Crohn’s disease, or when complications develop, treatment sometimes includes the removal of affected sections of ...
12
Working with IBD A Guide for Employers. Supporting employees living with Crohn s disease or ulcerative colitis
... bowel disease (IBD) is a medical term that describes a group of conditions in which the intestines become inflamed (red and swollen) and ulcerated (open sores that may ...Crohn’s disease and ulcerative ...
20
EVIDENCE BASED TREATMENT OF CROHN S DISEASE. Dr E Ndabaneze
... GradeA : : - - Evidence from large randomized clinical trials or meta Evidence from large randomized clinical trials or meta - - analysis of multiples randomized trial analysis of mul[r] ...
16
Pediatric Crohn's disease: epidemiology and emerging treatment options
... We have come a long way in our understanding of Crohn’s disease since it was first described in 1932. The last decade has been a period of rapid discoveries, especially in the field of metagenomics. It has been ...
13
Burden of Crohn’s disease: economics and quality of life aspects in Italy
... Crohn’s disease in the active phase and a Crohn’s Disease Activity Index score $150 were included in the ...Crohn’s disease in Italy was estimated to be €15,521 per year, with direct costs ...
10
Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease
... Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract that is characterized by recurrent relapses and periods of remission. Current therapies are aimed at inducing and maintaining ...
7
Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab
... Abstract: Adalimumab is a fully humanized anti-tumor necrosis factor alpha monoclonal antibody that was recently granted regulatory approval in the USA for the treatment of moder- ate to severe Crohn’s disease ...
8
Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
... bowel disease (IBD) is an important cause of morbidity and mortality for millions of patients ...Crohn’s disease (CD), particularly in patients who have previously failed biological ...
10
Maintenance treatment with infliximab for the management of Crohn’s disease in adults
... Crohn’s disease (CD) is a chronic, relapsing disease, the continuous cycle of which deeply affects the long-term course which, eventually, leads to fi brosis and development of transmural ...the ...
12
Crohn’s disease in women
... Crohn’s disease (CD). High incidence of the new onset of the disease in young women in their reproductive years demands special concern from physicians involved in their ...of disease activity index, ...
8
New biologics in the management of Crohn’s disease: focus on certolizumab pegol
... In vitro studies have demonstrated that infliximab, certolizumab, adalimumab, and etanercept are all able to neutralize soluble TNF- α and membrane-bound TNF- α . Infliximab and adalimumab are comparable in their ability ...
8
The multidisciplinary health care team in the management of stenosis in Crohn's disease
... Background: Stricture formation is a common complication of Crohn’s disease (CD), occurring in approximately one-third of all patients with this condition. Our aim was to summarize the available epidemiology data ...
13
Current and future role of biomarkers in Crohn's disease risk assessment and treatment
... Crohn’s disease (CD), a chronic inflammatory bowel disease (IBD), occurs in genetically susceptible individuals who develop aberrant immune responses to endoluminal ...
14
Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
... perianal disease and treating extra-intestinal manifestations are currently ...Crohn’s disease, instead of a step-wise approach starting with TNF antagonists followed by ustekinumab or vedolizumab or vice ...
14
Long-term outcome of laparoscopic and open surgery in patients with Crohn’s disease
... Methods: A total of 113 patients who had undergone first abdominal surgery due to Crohn’s disease between January 2000 and December 2010 in a maximum care provider facility, were included in the statistical ...
10
An evidence-based review of natalizumab therapy in the management of Crohn’s disease
... The most frequently reported adverse events with natalizumab infusion include headache, nausea, worsening of Crohn’s disease and nasopharyngitis. Other events include abdominal pain, arthralgias, fatigue, ...
8
Measuring patients’ satisfaction with their anti-TNF treatment in severe Crohn’s disease: scoring and psychometric validation of the Satisfaction for PAtients in Crohn’s diseasE Questionnaire (SPACE-Q<sup>©</sup>)
... There were 301 patients recruited by 32 physicians from March 2010 to July 2011. Seven patients who did not meet all the inclusion criteria and 15 who did not complete the SPACE-Q at any of the visits were excluded from ...
11